Our drugs are aimed at modulating a patient’s own immune system to enable it to overcome cancer or auto-immune conditions. Since our screening platform is unique, we believe our platform-derived targets are also unique. Hence, they confer a built-in advantage in developing a range of targets for immunotherapy. 4C Biomed has prioritised and experimentally validated, and is currently developing, antibodies in relation to the most promising of these targets.